# A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

> **NCT04575818** · PHASE1 · TERMINATED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG4059 oral suspension
- **DRUG:** Placebo
- **DRUG:** GLPG4059 tablet

## Key facts

- **NCT ID:** NCT04575818
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-16
- **Primary completion:** 2021-04-08
- **Final completion:** 2021-04-08
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Development of compound has been stopped
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04575818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04575818, "A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04575818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*